Eisai Co., Ltd. (4523) Press Release
Revenue of LEQEMBI (Preliminary Basis)
Earlier from Eisai
- Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Disease
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases